Format

Send to

Choose Destination
BMC Neurol. 2017 Apr 4;17(1):66. doi: 10.1186/s12883-017-0850-1.

Bapineuzumab for mild to moderate Alzheimer's disease: a meta-analysis of randomized controlled trials.

Author information

1
Faculty of Medicine, Ain Shams University, Cairo, Egypt.
2
NovaMed Medical Research Association, Cairo, Egypt.
3
Faculty of Medicine, Al-Azhar University, Cairo, Egypt.
4
Faculty of Medicine, Tanta University, Tanta, Egypt.
5
Faculty of Medicine, Benha University, Qaluobia, Egypt.
6
Faculty of Medicine, Zagazig University, Elsharkia, Egypt.
7
Faculty of Medicine, Damascus University, Damascus, Syria. Ammar.m.alsafadi@gmail.com.

Abstract

BACKGROUND:

Alzheimer's disease (AD) is a globally prevalent neurodegenerative condition, clinically characterized by progressive memory loss and gradual impairment of cognitive functions. Bapineuzumab is a fully humanized monoclonal antibody that binds to neurotoxic amyloid proteins in the brain, enhancing their clearance. We performed this systematic review and meta-analysis to evaluate the safety and efficacy of bapineuzumab in patients with mild to moderate Alzheimer's disease.

METHODS:

We performed a web-based literature search of PubMed, Ovid, EBSCO, Scopus, Embase, Cochrane CENTRAL, and web of science using the relevant keywords. Data were extracted from eligible records and pooled as mean difference (MD) or risk ratio (RR) values with their 95% confidence interval (CI), using Review Manager software (version 5.3 for windows). Heterogeneity was measured by Chi-square and I-square tests.

RESULT:

The pooled effect estimate from six randomized clinical trials (n = 2380) showed that bapineuzumab significantly reduced the cerebrospinal fluid concentration of phosphorylated tau proteins (Standardized MD = -5.53, 95% CI [-8.29, -2.76]). However, the bapineuzumab group was not superior to the placebo group in terms of change from baseline in Alzheimer's disease assessment scale (ADAS)-Cog11 (MD = 0.14, 95% CI [-0.72, 0.99]), disability assessment for dementia (DAD) scale (MD = 1.35, 95% CI [-1.74, 4.43]), and mini-mental state examination (MMSE) scores (MD = 0.08, 95% CI [-0.31, 0.47]). Regarding safety, bapineuzumab increased the risk of serious treatment-emergent adverse events (RR = 1.18, 95% CI [1.02, 1.37]) and cerebral vasogenic edema (RR = 40.88, 95% CI [11.94, 135.95]). All bapineuzumab doses (0.15, 0.5, 1, and 2 mg/kg) were similar to placebo in terms of change from baseline in ADAS-cog11, DAD, and MMSE scores, except for the 0.15 mg/kg dose, which caused a significant worsening on the ADAS-cog11 scale (MD = 5.6, 95% CI [0.22, 10.98]).

CONCLUSIONS:

Considering the lack of clinical efficacy, combined with the significant association with serious adverse events, bapineuzumab should not be used to treat patients with mild to moderate AD. Future studies should investigate the effect of combining bapineuzumab with other therapeutic strategies and reevaluate the efficacy of targeting amyloid β proteins in AD therapy.

KEYWORDS:

Alzheimer’s disease; Bapineuzumab; Dementia; Passive immunotherapy

PMID:
28376794
PMCID:
PMC5381133
DOI:
10.1186/s12883-017-0850-1
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center